Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 18/20 | 1.00 |
| ▸ | IDH2 | P48735 | 5/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763478 | 0.91 | IDH1 (0.84) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102478 | 0.91 | IDH1 (0.84) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29763272 | 0.88 | IDH1 (0.78) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102470 | 0.88 | IDH1 (0.78) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29763415 | 0.86 | IDH1 (0.75) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102459 | 0.86 | IDH1 (0.75) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL20018040 | 0.85 | IDH1 (0.75) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29763382 | 0.84 | IDH1 (0.72) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102495 | 0.84 | IDH1 (0.72) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102211 | 0.83 | IDH1 (0.84) | IDH1IDH2ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | PHARMARESROUCES (SHANGHAI) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-19 | — | — | US | disclosed |
| CN-111087353-B | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-10 | — | — | US | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3686190-A1 | SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS | Agios Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3686190-A1 | SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS | Agios Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| CN-111087353-A | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
| EP-3019483-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015003640-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015003640-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.